Skip to Main Content

In response to the financial hit many people are taking due to the coronavirus pandemic, Eli Lilly (LLY) is lowering the cost for most of its insulin products to $35 a month for anyone with commercial insurance or those who lack health coverage altogether.

The move, which will also reset copay cards to the same monthly $35 level, comes amid ongoing angst over the cost of the diabetes treatment. Insulin, in fact, has been something of a poster child for the national debate over prescription drugs costs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!